Growth Control and Cancer Metastasis publications

Correction: The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21

Soria-Valles C, Gutiérrez-Fernández A, Guiu M, Mari B, Fueyo A, Gomis RR and López-Otín C.

Oncogene (2019)

Regulation of death receptor signaling by the autophagy protein TP53INP2

Ivanova S, Polajnar M, Narbona-Perez AJ, Hernandez-Alvarez MI, Frager P, Slobodnyuk K, Plana N, Nebreda AR, Palacin M, Gomis RR, Behrends C and Zorzano A.

Embo J (2019)

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA and Gomis RR.

Nat Cell Biol, 20 (8), 990 (2018)

Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer

Cejalvo JM, Pascual T, Fernández-Martínez A, Brasó-Maristany F, Gomis RR, Perou CM, Muñoz M and Prat A.

Cancer Treat Rev, 67 63-70 (2018)

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D, Bowman A, Liversedge V, De Boer RH, Passos-Coelho JL, O'Reilly S, Bertelli G, Joffe J, Brown JE, Wilson C, Tercero JC, Jean-Mairet J, Gomis R and Cameron D.

J Bone Oncol, 13 123-135 (2018)

CANCERTOOL: A Visualization and Representation Interface to Exploit Cancer Datasets

Cortazar AR, Torrano V, Martín-Martín N, Caro-Maldonado A, Camacho L, Hermanova I, Guruceaga E, Lorenzo-Martín LF, Caloto R, Gomis RR, Apaolaza I, Quesada V, Trka J, Gomez-Muñoz A, Vincent S, Bustelo XR, Planes FJ, Aransay AM and Carracedo A.

Cancer Res, 78 (21), 6320-6328 (2018)

Loxl2 is dispensable for dermal development, homeostasis and tumour stroma formation

Kober KI, Cano A, Géraud C, Sipilä K, Mobasseri SA, Philippeos C, Pisco AO, Stannard A, Martin A, Salvador F, Santos V, Boutros M, Rognoni E and Watt FM.

PLoS One, 13 (6), e0199679 (2018)

Organ-specific metastases

Urosevic J and Gomis RR.

Nature Biomedical Engineering, 2 (6), 347-348 (2018)

CLK2 blockade modulates alternative splicing compromising MYC-driven breast tumors

Salvador F and Gomis RR.

EMBO Mol Med, 10 (6), (2018)

Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer

Cejalvo JM, Pascual T, Fernández-Martínez A, Brasó-Maristany F, Gomis RR, Perou CM, Muñoz M, Prat A.

Cancer Treat Rev (2018)